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Introduction
Two important characteristics distinguish stem cells from other 
cells. Firstly, they are unspecialized cells that have the ability to 
renew themselves through cell division, and secondly under 
certain conditions they can be induced to become tissue or 
organ-specific cells with special functions.
Until recently, scientists have mainly worked with embryonic 
stem cells and somatic stem cells. Embryonic stem cells are 
from the blastocyst of the embryo. The blastocyst is composed 
of an inner cell mass of stem cells that differentiate into differ-
ent types of cells, giving rise to the entire body of the organism. 
Embryonic stem cells are donated for research purposes by 
eggs that have been fertilized in vitro, and they are not derived 
from eggs fertilized in a women’s body. The donated stem cells 
are transferred to a culture dish that contains a nutrient broth 
called a culture medium where they divide and spread over the 
surface of the culture dish. When stem cells are grown under 
specific conditions, they can remain unspecialized. If the stem cells 
are allowed to clump together to form embryoid bodies, sponta-
neously they will begin to differentiate. Scientists can modify the 
stem cells by inserting specific genes or by changing the chemical 
make-up of the culture. Figure 1 illustrates the process of modify-
ing stem cells to become gene specific stem cells.
Adult stem cells are different from embryonic stem cells be-
cause they are found in mature tissues or organs. Adult stem 
cells are undifferentiated cells that can develop into specific 
cells of the tissue or organ where it is found. Adult stem cells 
are found in a specialized region called the stem cell niche. 
When needed the stem cells will divide and differentiate. This 
can occur when there is tissue damage or under normal wear 
and tear conditions – the stem cells will divide in order to re-
plenish the supply of cells. There are various types of adult stem 
cells that can differentiate into numerous types of cells hemato-
poietic stem cells (develop into blood cells), mesenchymal stem 
cells (develop into bone cells, cartilage cells and fat cells), and 
neural stem cells (develop into cells of the nervous system).
Human induced pluripotent stem cells are an additional type of 
stem cell. This stem cell is an adult cell that has been genetically 
reprogrammed to express the characteristics of an embryonic 
stem cell. The method used to reprogram these cells help re-
searchers learn more about the possibility of reprogramming 
damaged or diseased cells in the human body. 
Human stem cells have many uses in research and clinic. The 
most important use being cell-based therapy. Cell-based therapy 
is the potential to direct the differentiation of stem cells in order 
to transplant them as replacement cells or tissue. Today, tissue 
and organs are being donated, but the need for transplantable 
organs and tissue far outweighs the supply. Cell-based therapy 
can offer a renewable source of replacement cells which can be 
used to treat different diseases. (Bethesda, 2016).
There are several drawbacks of using transplanted stem cells to treat 
disease including rejection and long-term side effects are not known. 
Therefore, a lot of research is still being done before stem cell ther-
apy is used as an established treatment for disease.  (Ladock, 2016).
One disease scientists believe stem cell therapy can treat is mac-
ular degeneration. Macular degeneration is the most common 
cause of vision loss affecting more than 10 million Americans.
Abstract
Macular degeneration is the leading cause of vision loss in Americans sixty years and older. Currently, it is an incurable 
disease. Stem cell therapy is the idea of transplanting stem cells to replace damaged cells in the body. As the demand 
for transplantable organs far outweighs the supply, stem cells are an encouraging alternative to replace damaged cells. 
Can stem cell therapy be the first cure for macular degeneration? Many experiments have been done on transplanting 
stem cells into the eyes of rats with macular degeneration yielding promising results. The first transplantation of retinal 
pigmented epithelial stem cells into humans to treat macular degeneration was done in 2012. Stem cells were differ-
entiated and inserted into two patients suffering from macular degeneration. Both patients that partook in the study 
displayed significant visual improvement, and no abnormal growth was observed. In another study, the use of retinal 
epithelial cells vs. the use of other types of eye cells to treat macular degeneration was studied. Each cell type has the 
same potential for use in stem cell therapy. Stem cell therapy is a hopeful option for treatment of macular degeneration. 
Further research is needed before it can be used as a widespread cure.
Stem Cell Therapy and Macular Degeneration
Brenda Stern
Brenda Stern graduated in June 2016 with a BS in Biology, and is accepted to SUNY School of Optometry
Figure 1: Stem cells 
clump together to 
form embryoid bodies, 
and spontaneously 
they will begin to 
differentiate. The stem 
cells can be modified 
by inserting specific 
genes. (Bethesda, 
2016)
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The retina is the part of the eye that records the images we see 
and sends them via the optic nerve to the brain. The macula is 
located in the central area of the retina and is responsible for 
focusing central vision, seeing fine details, and recognizing faces 
and color. The anatomy of the human eye is illustrated in figure 
2 with the location of the macula shown. Macular degeneration 
is a disease which causes the deterioration of the cells of the 
macula. At the present time it is an incurable disease.
Age-related macular degeneration is the most common cause of 
blindness in people over the age of 60 years old. Age-related mac-
ular degeneration gets progressively worse as one ages. It starts 
with the dysfunction and death of retinal pigment epithelial (RPE) 
cells. It continues with photoreceptor loss, and insufficiencies 
in high acuity vision. There are 3 stages of age-related macular 
degeneration. Early age-related macular degeneration is the first 
stage where vision loss is not experienced. It can be diagnosed by 
the presence of small yellow droplets beneath the retina called 
drusen. The second stage is called intermediate age-related mac-
ular degeneration where some vision loss may be experienced. A 
comprehensive eye exam will look for drusen or pigment change 
in the retina. The last stage is called late age-related macular de-
generation. At this stage vision loss is noticeable. (Buchholz, 2009)
It is known that the causes of macular degeneration are both 
genetic and environmental, but the exact cause is not known. 
Age is the biggest risk; there is more of a chance one will devel-
op macular degeneration as one ages. (Akpek, 2013).
Methods
Literature for this article was obtained primarily using Touro 
College Online library. Other databases such as PubMed were 
used. Additionally, Google Scholar was valuable for finding nec-
essary and relevant articles.
Discussion
Only 5.5 millimeters in diameter, the macula is a part of the 
retina that is responsible for central vision. Researchers have 
been studying the possibility of using stem cells to treat mac-
ular degeneration. The macula is made up of photoreceptor 
cells called rods and cones. Rods and cones respond to light by 
sending electrical impulses to the brain through the optic nerve. 
The brain then interprets these impulses. Behind the rods and 
cones is a layer of cells called retinal pigmented epithelial cells. 
(ISSCR, 2015).
Functions of Retinal Pigmented Epithelium
Retinal pigmented epithelial cells have many functions in the 
eye. Firstly, these cells are responsible for transport in two 
directions. In one direction they transport glucose and other 
nutrients from the blood to the rods and cones. In the other 
direction the transport electrolytes and water from the subret-
inal area to the choroid. Another function of retinal pigmented 
epithelial cells is to absorb and filter entering light. The retina 
is made up of various pigments that are sensitive to different 
wavelengths of light. Additionally, retinal pigmented epithelial 
cells are responsible for phagocytosis.  (Simó Et. Al. 2010) 
The eye is an excellent part of the body for researchers to test 
stem cell therapy on because the eye is well contained by its 
many barriers. It is hard for the stem cells to move to other 
parts of the body. Additionally, researchers can assess the differ-
ences between a treated and untreated eye on the same patient. 
There is equipment available that allows one to see the interior 
and exterior of a person’s eye.   
The focus of scientists has been on using retinal pigmented 
epithelial cells for stem cell therapy. This is because it is a lot 
harder to ensure the proper placement of rods and cones in a 
patient’s eye. Rods and cones connect with nerve fibers, and it is 
extremely complex to correctly integrate these photoreceptor 
cells with the nerve fibers. Retinal pigmented epithelial cells do 
not connect to nerve fibers; therefore they are a better option 
for stem cell therapy. 
It is the goal of scientists to be able to transplant retinal pigment-
ed epithelial cells before the disease has progressed such that 
the photoreceptor cells have died. In this way, the transplanted 
retinal pigmented epithelial cells can take on some function of 
the damaged retinal pigmented epithelial cells and prevent the 
rod and cone cells from dying, thereby stopping the progression 
of the disease. (ISSCR, 2015).
Delivery of Stem Cells into the Eye
The following method was used to deliver retinal epithelial 
cells into rats. The rat was put under anesthesia. A sharp ster-
ilized needle was inserted to make a hole right beneath the 
limbus, which is the border between the cornea and the sclera 
Figure 2: Anatomy of the human eye showing the location 
of the macula. (ISSCR, 2015)
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of the eye. The tip of the syringe was inserted into the hole, 
injecting the retinal pigmented epithelial cells. The syringe was 
then taken out slowly, and eye moisturizing drops were given. 
(Westenskow Et. Al. 2015). 
A study of rats with macular degeneration, treated with human 
embryonic stem cells has shown evidence of rescued photo-
receptors and vision loss prevention. Three different levels of 
pigmented cells were used; light, medium and heavy. Different 
amount of cells were used in each group of rats. Visual acuity 
improved in the groups of rats treated with a dose of between 
5,000 – 100,000 retinal pigmented epithelial cells. The cells in-
jected into the rats sustained visual function for at least 60 days. 
The cells survived in the rats for at least 220 days. All the groups 
of rats showed deterioration of visual acuity over time. There 
is no evidence that showed any group having a slower deteri-
oration over time. The deterioration of the visual acuity of the 
rats in this study may be related to the inadequate use of im-
munosuppressive drugs to treat the rats. Another hypothesis of 
why the cells didn’t last is that cell transplantation may need to 
be repeated several times in order to sustain their therapeutic 
effect. The study confirmed the long-term safety of retinal pig-
mented epithelial cells for treatment of macular degeneration 
in rats. It is a promising step in the research of stem cell therapy 
to treat specific types of macular degeneration in humans. (Lu 
Et. Al. 2009).
In one study researchers tested whether human embryonic 
stem cells can safely be used to treat patients with macular 
degeneration. Although human embryonic stem cells were first 
discovered in 1998, this was the first study to report trans-
planting human embryonic stem cells into human patients. The 
study tested for signs of hyperproliferation, carcinogenicity, 
abnormal tissue formation, and rejection. Two patients were 
selected for the study. One patient had dry age-related macular 
degeneration and the other had Stargardt’s macular dystrophy 
(most common pediatric macular degeneration). (Schwartz Et. 
Al. 2012). 
In the experiment human embryonic stem cell culture MA09 
(classification of human embryonic stem cells) were used to 
generate a master cell bank. (Schwartz Et. Al. 2012) Cell line 
MA09 has contact with the environment before transplanted 
into the patient and therefore is classified as a xenotransplan-
tation. Xenotransplantation is any procedure that involves the 
transplantation, infusion, or implantation to humans of nonhu-
man live cells. (Samdani, 2014)  After embryoid bodies were 
formed and there was multiplication of the cells, retinal pigment 
epithelial patches were isolated. Embryoid bodies are the first 
phase of embryonic stem cell differentiation. There are various 
ways to form embryoid bodies, but it has been a challenge to 
form embryoid bodies uniform in size. (Xu Et. Al. 2011) The 
retinal pigmented epithelial cells were tested for pathogens and 
phagocytosis. They were also tested for RPE and hESC markers.
Human embryonic retinal pigment cells were successfully cul-
tured. The cells showed typical retinal pigmented epithelial cell 
behavior by losing their pigmented cobblestone morphology 
during proliferation and re-differentiating into a monolayer of 
polygonal cuboidal pigmented epithelium.
One hundred and fifty nanoliters of retinal pigmented epithelial 
cells were injected into the patients’ eyes through a cannula that 
delivered a dose of 500,000 viable retinal pigmented epithelial 
cells into the subretinal space. Immunosuppressive drugs; tacro-
limus and mycophenolate mofetil were given to each patient a 
week before the surgery and continued for six weeks after the 
surgery. Tacrolimus was not given after week six and the myco-
phenolate mofetil was continued for an additional six weeks. 
(Schwartz Et. Al. 2012).
There was no hyperproliferation or abnormal growth in either 
of the patients following surgery as determined by biomicro-
scopic and ophthalmoscopic clinical examinations. (Schwartz Et. 
Al. 2012).  
Anatomical evidence showed survival of human embryonic 
stem cells in the patient with Stargardt’s macular dystrophy. The 
transplanted cells were localized to exactly the correct ana-
tomical location. Increased pigmentation was seen in the retinal 
pigmented epithelial cells beginning from week one after the 
surgery up until month three after the surgery. 
The patient with age-related macular degeneration did not take 
the immunosuppressive drugs after the operation; therefore 
anatomical evidence was difficult to confirm. 
Both patients displayed functional visual improvement. The 
Figure 3: A 
series of images 
showing the 
macula before 
the operation 
until after the 
operation. 
Increased RPE 
are seen post 
operation. 
(Schwartz Et. 
Al. 2012)
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patient with Stargardt’s macular dystrophy was able to read study 
letters of 20/500 immediately following surgery. By week six, the 
patient was reading letters of 20/320 which remained stable 
through the postoperative period. The patient with age-related 
macular degeneration showed mild visual improvements. 
The series of images in figure 4 illustrate the area in the eye called 
the macula from before the operation until after the operation. 
Increased retinal pigmented epithelial cells are seen post operation. 
In this study human embryonic stem cells were safely trans-
planted into 2 patients. (Schwartz Et. Al. 2012). 
A second study compared the effectiveness of using human in-
duced pluripotent cells with using human embryonic stem cells. 
Both types of stem cells have the ability to differentiate, but it is 
unclear if they both have the same potential for use in stem cell 
therapy. The results were determined by finding differentiating 
ocular cells called retinal pigmented epithelium (RPE). 
Transcription factors, protein arrangement, and gene expression 
were looked at when comparing the two types of stem cells. 
The study concluded that human induced pluripotent stem 
cells are a feasible candidate for cellular therapy since they have 
similar cellular function and possess proper gene expression. 
(Buchholz Et. Al. 2009).
Where we are now
There are still several difficulties that must be overcome before 
stem cell therapy is used as a widespread treatment. Many con-
tinued years of research are needed. 
There are legal and ethical issues with using embryonic stem 
cells for stem cell therapy; therefore, a lot of effort is being put 
into generating induced pluripotent stem cells. There is a risk, 
however, that the induced pluripotent stem cells will turn into 
cancer cells, and that is a risk not worth taking. Therefore, it has 
been a challenge for researchers to obtain a readily available 
bank of stem cells to be used for stem cell therapy.
Can the stem cell therapy be effective if the condition that 
caused the cells to die in the first place is still present? Most 
likely, stem cell therapy will need to be combined with addition-
al treatments in order to limit further damage in macular de-
generation patients. These additional treatments are still being 
researched and developed.
An additional difficulty that must be overcome is to find out 
what exactly is the correct dosage of cells to transplant. There 
have only been a limited number of clinical procedures done. 
In order to figure out the correct dosage more clinical studies 
must be performed. 
Scar tissue is present in the damaged eyes of patients with mac-
ular degeneration. When new cells are transplanted there is a 
barrier between the host retina and the grafted cells. This can 
affect the way the light is transmitted, and the way the patients 
will see. Treating patients before scar tissue has formed, or dis-
covering ways to get rid of scar tissue is crucial before stem 
cells can be transplanted. (Barnstable). 
Conclusion
There is promising research for use of retinal pigmented epi-
thelial cells to treat macular degeneration. Continued research 
is needed before stem cell therapy can be used as a widespread 
treatment for macular degeneration. It is a goal of researchers 
to treat patients earlier on in the progression of the disease, 
before complete visual function has been lost. 
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